| 1 | |
|----|---|
| 2 | |
| 3 | |
| 4 | Efficacy and safety of ethanolamine oleate in sclerotherapy in patients with |
| 5 | difficult-to-resect venous malformations: A multicenter, open-label, |
| 6 | single-arm study |
| 7 | Running head: Ethanolamine oleate sclerotherapy in difficult-to-resect venous |
| 8 | malformations |
| 9 | |
| 10 | |
| 11 | Mine Ozaki ^{1*} , Tadashi Nomura ² , Keigo Osuga ³ , Masakazu Kurita ⁴ , Ayato Hayashi ^{5,6} , |
| 12 | Shunsuke Yuzuriha ⁷ , Noriko Aramaki-Hattori ⁸ , Makoto Hikosaka ⁹ , Taiki Nozaki ¹⁰ , |
| 13 | Michio Ozeki ¹¹ , Junko Ochi ¹² , Shimpei Akiyama ¹³ , Yasumasa Kakei ^{14,15} , Keiko |
| 14 | Miyakoda ¹⁵ , Naoko Kashiwagi ¹⁵ , Takahiro Yasuda ^{15,16} , Yuki Iwashina ¹ , Tsuyoshi |
| 15 | Kaneko ⁹ , Kiyoko Kamibeppu ¹⁷ , Takafumi Soejima ¹⁸ , Kiyonori Harii ¹ |
| 16 | |
| 17 | ¹ Department of Plastic Surgery, Kyorin University Faculty of Medicine, Tokyo, Japan |
| 18 | ² Department of Plastic Surgery, Kobe University Graduate School of Medicine, Hyogo, |
| 19 | Japan |
| 20 | ³ Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, |
| 21 | Osaka, Japan |
| 22 | ⁴ Department of Plastic and Reconstructive Surgery, The University of Tokyo Hospital, |
| 23 | Tokyo, Japan |

- ⁵ Department of Plastic and Reconstructive Surgery, Yokohama City University,
- 25 Kanagawa, Japan
- ⁶ Department of Plastic and Reconstructive Surgery, Juntendo University School of
- 27 Medicine, Tokyo, Japan
- ⁷ Department of Plastic and Reconstructive Surgery, Shinshu University School of
- 29 Medicine, Nagano, Japan
- ⁸ Department of Plastic and Reconstructive Surgery, Keio University School of Medicine,
- 31 Tokyo, Japan
- ⁹Department of Plastic and Reconstructive Surgery, National Center for Child Health and
- 33 Development, Tokyo, Japan
- ¹⁰Department of Radiology, Keio University School of Medicine, Tokyo, Japan
- ¹¹ Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan
- ¹² Department of Diagnostic Radiology, Suita Tokushukai Hospital, Osaka, Japan
- ¹³ Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan
- ¹⁴ Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of
- 39 Medicine, Hyogo, Japan
- 40 ¹⁵ Department of Medical Devices, Kobe University Graduate School of Medicine,
- 41 Hyogo, Japan
- 42 ¹⁶ Advanced Medical-Engineering Development Center, Kobe University, Hyogo, Japan
- 43 ¹⁷ Division of Health Sciences and Nursing, Graduate School of Medicine, the
- 44 University of Tokyo, Tokyo, Japan
- ¹⁸ Department of Child Health Nursing, Kobe University Graduate School of Health
- 46 Sciences, Hyogo, Japan

47

- 48 * Corresponding author:
- 49 E-mail: <u>zakimin@nifty.com</u> (MO)

51 Abstract

52 **Objective**

- 53 To evaluate the efficacy and safety of sclerotherapy in patients with difficult-to-resect
- 54 venous malformations treated with ethanolamine oleate.

55 **Design and setting**

- 56 This investigator-initiated clinical trial employed a multicenter, single-arm, open-label
- 57 design and was conducted in Japan.

58 **Patients**

- 59 Overall, 44 patients with difficult-to-resect venous malformations were categorized into
- 60 two cohorts: 22 patients with cystic-type malformations and 22 patients with diffuse-type
- 61 malformations.

62 Interventions

- 63 Patients received injections of 5% ethanolamine oleate solution, double diluted with
- 64 contrast or normal saline, with a maximum dose of 0.4 mL/kg. The same method of
- administration was used for children (<15 years old). The maximum volume of the
- 66 prepared solution in one treatment was 30 mL.

67 Evaluation methods

- 68 Treatment efficacy was assessed by evaluating changes in lesion volume using magnetic
- 69 resonance imaging and changes in pain using a visual analog scale.
- 70 Results
- Among the 45 patients who consented, one was excluded owing to potential intracranial
- 72 involvement of venous malformations during screening. Regarding the primary outcome,
- 73 26 of 44 patients (59.1%, 95% confidence interval: 44.41-72.31%) achieved $\ge 20\%$
- reduction in malformation volume, with 16 patients having cystic lesions (72.7%,
- 75 51.85–86.85%) and 10 patients having diffuse lesions (45.5%, 26.92–65.34%). Both
- 76 cohorts showed significant improvement in self-reported pain scores associated with
- 177 lesions 3 months post-sclerotherapy. No death or serious adverse events occurred.
- 78 Hemoglobinuria was observed in 23 patients (52%), a known drug-related adverse event.
- 79 Prompt initiation of haptoglobin therapy led to full recovery within a month for these
- 80 patients.
- 81 Conclusions
- 82 Ethanolamine oleate shows potential as a therapeutic sclerosing agent for patients with
- 83 difficult-to-resect venous malformations.
- 84

- 85 Keywords: sclerotherapy, ethanolamine oleate, venous malformation, cavernous
- 86 hemangioma, hemoglobinuria

88 Introduction

| 89 | Venous malformations (VMs) are vascular developmental abnormalities that |
|-----|---|
| 90 | arise during fetal life and are associated with pain, movement disorders, and other |
| 91 | symptoms [1-3]. A study conducted by the Ministry of Health, Labor and Welfare in |
| 92 | Japan (Project on Intractable Hemangioma, Vascular Malformation, Lymphangioma, |
| 93 | Lymphangiomatosis and Related Diseases in Fiscal 2014) estimated that 20,000 |
| 94 | individuals are affected by VMs, with half of them harboring difficult-to-resect lesions |
| 95 | due to extensive involvement or muscle infiltration [4,5]. For such cases, sclerotherapy is |
| 96 | the treatment of choice [2,6-9]. |
| 97 | Sclerotherapy is a globally recognized treatment for VMs, described as among |
| 98 | the most effective options available. Ethanolamine oleate, a sclerosing agent, has been |
| 99 | extensively documented in this regard [10]. American guidelines for percutaneous |
| 100 | sclerotherapy for head and neck venous and lymphatic malformations [11] and European |
| 101 | guidelines for sclerotherapy in chronic venous disorders both acknowledge the |
| 102 | effectiveness of sclerotherapy in chronic venous disorders, including VMs [12]. However, |
| 103 | to the best of our knowledge, sclerotherapy for VMs remains uncovered by health |
| 104 | insurance policies, with no pharmaceutical approval for any sclerosing agent across |
| 105 | countries to date. |
| 106 | In Japan, ethanolamine oleate, absolute ethanol, and polidocanol have been used |
| 107 | as off-label sclerosing agents for VM treatment [13-17]. While absolute ethanol and |
| 108 | polidocanol are associated with serious, life-threatening adverse events [11,18,19], |
| 109 | ethanolamine oleate is considered a safer option with minimal adverse events [20]. |
| 110 | Horbach et al.'s article [20], which analyzed five studies encompassing 188 patients |
| 111 | treated with ethanolamine oleate for venous or lymphatic malformations, reported skin |

| 112 | ulceration and skin necrosis (six cases, 3%) as adverse events. However, systemic |
|-----|---|
| 113 | adverse events, facial nerve disorders, or other adverse events were absent [20]. In |
| 114 | another study that evaluated the cytotoxicity of each sclerosing agent in muscle tissue, |
| 115 | absolute ethanol was the most cytotoxic, with ethanolamine oleate and polidocanol |
| 116 | exhibiting comparably lower cytotoxicity [14]. Conversely, efficacy studies have shown |
| 117 | promising results for ethanolamine oleate, which reduced lesions and improved |
| 118 | symptoms in 88-100% of cases evaluated in a systematic review [20]. Furthermore, a |
| 119 | pediatric-centered study examined its application in children (mean age: 15.1 years, |
| 120 | range: 3 months to 21 years) among 83 patients (comprising 85 procedures), resulting in |
| 121 | complete symptom resolution for 79 lesions and notable enhancements for six lesions |
| 122 | [21]. Although ethanolamine oleate is currently approved as a sclerosing agent for |
| 123 | esophageal and gastric varices in Japan [22,23], its use has not been indicated for |
| 124 | pediatric patients. This is particularly relevant considering the congenital nature of VMs, |
| 125 | often requiring treatment in children. Nevertheless, existing evidence suggests its |
| 126 | efficacy in pediatric patients. |
| 127 | Given its efficacy and safety profile, ethanolamine oleate is regarded as the most |
| 128 | appropriate candidate for initial regulatory approval as a sclerosing agent for VMs. A |
| 129 | limited number of well-designed clinical trials have investigated treatment options for |
| 130 | difficult-to-resect VMs; we initiated a phase III, multicenter, open-label, single-arm |
| 131 | clinical trial to aid the Japanese government in approving health insurance coverage. |
| 132 | Based on their morphological characteristics, VMs can be broadly categorized into cystic |
| 133 | and diffuse lesions. Cystic lesions are more likely to shrink with sclerotherapy, whereas |
| 134 | diffuse lesions are less likely to respond [24]. Consequently, the study design employed |
| 135 | volume reduction and pain improvement as the evaluation criteria for cystic and diffuse |
| | |

- 136 lesions, respectively. This clinical trial aimed to characterize the clinical impact of
- 137 ethanolamine oleate injection in patients with difficult-to-resect VMs.

138

139 Materials and methods

140 Study design and procedure

| 141 | This non-randomized, prospective, open-label, multicenter clinical trial was |
|-----|---|
| 142 | conducted at eight hospitals from January 1, 2021 to the end of April 2023 (the last |
| 143 | patient's visit). The recruitment period for Kyorin University Hospital, Kobe University |
| 144 | Hospital, Osaka Medical and Pharmaceutical University Hospital, The University of |
| 145 | Tokyo Hospital, Juntendo University Urayasu Hospital, and National Center for Child |
| 146 | Health and Development Hospital was from 1/1/2021 to 31/3/2023; for Shinshu |
| 147 | University Hospital, the recruitment period was from 1/2/2021 to 31/3/2023; for Keio |
| 148 | University Hospital, the recruitment period was from 19/3/2021 to the 31/3/2023. A |
| 149 | summary of this study is presented in Fig 1. The observation period continued for 3 |
| 150 | months following the intervention. Participants were instructed to visit at designated |
| 151 | times during the observation period and provided with reimbursement for travel expenses |
| 152 | to reduce the burden on patients. Written informed consent was obtained from all patients |
| 153 | or their parents/guardians if the patient was under 20 years old. This clinical trial was |
| 154 | approved by the Institutional Review Board of each facility (Kyorin University Hospital, |

1 . . .

·.

| 155 | Kobe University Hospital, Osaka Medical and Pharmaceutical University Hospital, |
|-----|--|
| 156 | Shinshu University Hospital, The University of Tokyo Hospital, Juntendo University |

3 6 11

- 157 Urayasu Hospital, Keio University Hospital, National Center for Child Health and
- 158 Development Hospital). The study protocol adhered to the SPIRIT statement. All data
- 159 were stored and archived at the Data Center of DOT World Co., Ltd., Tokyo, Japan.
- 160
- 161 **Fig 1. Summary of the study protocol**. MRI, magnetic resonance imaging; CT,
- 162 computed tomography
- 163

164 Sample size calculation

165 Considering cystic lesions, the threshold for volume reduction was set at a 166 minimum of 20%. This was based on the assumption that successful treatment should 167 improve the conditions of a proportion of patients, achieving either complete response 168 (target lesion resolved) or partial response ($\geq 20\%$ target lesion volume reduction). 169 Limited data exist regarding magnetic resonance imaging (MRI)-based evaluations for 170 ethanolamine oleate in difficult-to-resect VMs. Kaji et al. [7] reported a median 171 MRI-based lesion reduction rate of approximately 25% in 60 participants with VMs. 172 Because the median corresponds to the 50th percentile of the data distribution, more than 173 50% of patients are expected to experience a reduction rate \geq 20%, as shown in the figure 174 presented by Kaji et al. A study conducted by Alexander et al. [25] reported on 175 MRI-based reduction rates for VMs and demonstrated that at least 50% of participants 176 achieved a reduction rate $\geq 20\%$ [25].

177 It should be noted that Kaji et al. [7] calculated the lesion reduction rate from the 178 measured area of the lesion. Although Kaji's method differs from that used in the current 179 study, we considered the reduction rate reported in these previous studies to be suitable 180 since the expected threshold and complete response and partial response values in the 181 present study would be at least 50% [25]. 182 It was estimated that the present trial required the inclusion of 19 cases per group

182 In was estimated that the present that required the inclusion of 19 cases per group 183 to obtain 80% statistical power to detect significant between-group differences based on a 184 binomial distribution with a one-sided 2.5% significance level. Considering potential 185 dropout cases, the target number of patients with cystic lesions was set to 22. The same 186 target was used for cases with diffuse lesions, and a total of 44 cases were targeted for 187 recruitment.

188

189 **Participant inclusion criteria**

190 Participants were selected according to the inclusion criteria set by investigators 191 collecting patient information during outpatient consultations at each facility among the 192 patients with VMs introduced at each facility. The inclusion criteria were any age; 193 informed consent, either directly or through their legal guardians if under 20 years old; 194 and VMs considered challenging to surgically remove, with sclerotherapy identified as 195 the primary treatment option. Difficulty in resection was defined by the investigator or 196 sub-investigator as a high risk of lifestyle dysfunction due to potential complications 197 from excision or the risk of aesthetic impairment. 198 Moreover, patients needed to exhibit at least one target VM with a major axis

diameter \geq 30 mm in the extremities or \geq 20 mm in the head and neck, as determined on MRI or computed tomography. Additionally, inclusion criteria stipulated the absence of a

- 201 thrombus or organized tissue that could interfere with the evaluation of images or the
- 202 judgment of treatment effectiveness in target VMs.
- 203

204 **Participant exclusion criteria**

- 205 The exclusion criteria included multiple organ failure or disseminated
- 206 intravascular coagulation; currently taking or recently started taking medications known
- 207 to influence lesion resolution, such as propranolol or specific herbal medicines like
- 208 Kamishoyosan or Ninjinyoeito; diabetes mellitus (HbA1c ≥8.0) or autoimmune
- 209 disorders; Child–Pugh Class C liver dysfunction; renal dysfunction (estimated
- 210 Glomerular Filtration Rate <60 mL/min/1.73 m²); or cardiac dysfunction (New York
- 211 Heart Association Class \geq 2).
- 212 Further exclusions encompassed patients who had undergone sclerotherapy
- 213 within 6 months preceding signing of the informed consent, with a history of allergy to
- 214 ethanolamine oleate or angiography contrast agents, and those who had undergone
- surgery exceeding 45 min within 2 weeks preceding signing of the informed consent.
- 216 Additionally, participation in other clinical studies within 4 weeks preceding signing of
- 217 the informed consent, pregnancy, potential pregnancy, or lactation rendered individuals
- 218 ineligible. Lastly, patients deemed ineligible by the investigator or sub-investigator were
- 219 not enrolled.
- 220

221 Intervention

The following procedures were performed by the investigator from each facility under general anesthesia in the operating room. Patients received injections of 5% ethanolamine oleate solution, double diluted with contrast or normal saline (Fig 2), with a

225 maximum dose of 0.4 mL/kg. The same method of administration was used for children 226 (<15 years old). The maximum volume of the prepared drug in one treatment was 30 mL. 227 The safety of this dose is within the range approved for gastric variceal treatment in Japan 228 [22], and its efficacy has been reported in previous studies [7,13,15-17]. The drug is 229 administered only once; however, for patients with diffuse lesions, if there is little 230 improvement in symptoms such as pain even after 4 weeks from administration, and the 231 principal investigator deems it necessary for treatment, additional dosing is permitted. In 232 such cases, the dosage should be the same as the initial dose. 233 234 Fig 2. Sclerotherapy procedure for venous malformations. (A) Adjust the position of 235 the fluoroscopy device. (B) Insert a needle under ultrasound guidance. (C) Ultrasound 236 image at the time (B-mode). The inserted needle is visible (arrow). (D) Apply negative 237 pressure to confirm the presence of back flow (arrow). (E) During digital subtraction 238 angiography, contrast is injected to confirm the location of the lesion and outflow 239 pathways. Once it is confirmed that the needle is in the appropriate position and the 240 injection volume is verified, inject the sclerosing agent diluted with contrast. (F) 241 Fluoroscopy after multiple iterations of this process showing the persistence of the 242 sclerosing agent within the lesion due to the contrast mixture. (G) Ultrasound imaging 243 confirming the presence of a sclerosing agent under ultrasound guidance. 244

245 Endpoints

The primary endpoint was achieving a ≥ 20% VM volume reduction 3 months
post-intervention. This endpoint was chosen based on the assumption that a positive
correlation between VM symptoms and lesion volume translates to clinical efficacy [26].

249 MRI scans were outsourced to an external institution for lesion volume analysis. 250 Afterwards, the images were separately evaluated by two independent board-certified 251 radiologists using the image analysis software OsiriX (PixMeo SARL, Geneva, 252 Switzerland) (Fig 3). The final value was determined by averaging the measurements 253 obtained by each evaluator. The interobserver correlation coefficient (2,1) was calculated 254 to assess the reproducibility of the measurements between the evaluators. 255 The key secondary endpoint was improvement in symptoms, particularly 256 self-reported, lesion-associated pain scores, 3 months post-intervention. Patients aged 2 257 to 5 years were evaluated using the face scale (range: 1–6), developed by Wong-Baker 258 [27], whereas those aged \geq 6 years were evaluated using a visual analog scale (VAS) 259 (range: 0–100). Two-time scales were assessed using the VAS: maximum pain within 24 260 h and maximum pain within 1 week. 261 Adverse events and adverse drug reactions were documented to evaluate safety 262 endpoints. The severity of adverse events was determined based on the following criteria: 263 grade 1 denoted mild signs or symptoms that were easily tolerable, grade 2 denoted 264 moderate signs or symptoms that interfered with daily activities, and grade 3 denoted 265 severe signs or symptoms that significantly impacted daily life.

266

Fig 3. A woman in her thirties with a painful intramuscular VM in the right thigh.

268 (A,B) Magnetic resonance imaging (MRI) before sclerotherapy (T2-weighted images:

axial and coronal views). (C) One slide of the image subjected to segmentation using

- 270 OsiriX (image analysis software) on MRI before sclerotherapy. (D) Digital subtraction
- angiography during sclerotherapy showing the administration of the sclerosing agent
- diluted with contrast. (E,F) MRI 3 months after sclerotherapy (T2-weighted images: axial

and coronal views), confirming lesion volume reduction. The patient reported the

- resolution of pain at this time.
- 275

276 Statistical analysis of endpoints

277 The full analysis set comprised all patients who underwent the study intervention, 278 ensuring a comprehensive evaluation of treatment outcomes. In contrast, the per-protocol 279 set excluded patients deemed ineligible post-enrollment and those exhibiting severe 280 protocol violations. This approach aimed to uphold the integrity of the analysis by 281 focusing on patients who adhered closely to the study protocol. The safety analysis set 282 was identical to the full analysis set. 283 Primary analyses compared the number of patients who achieved $\geq 20\%$ VM 284 volume reduction 3 months after sclerotherapy relative to the baseline value using a

one-sided binomial test with a significance level of p < 0.025 (one-sided). The 95%

286 confidence intervals (CIs) for the proportion of patients achieving this reduction were

estimated using the scoring method. This analysis was performed separately according to

288 VM type.

Secondary analyses evaluated lesion-associated pain scores 3 months after sclerotherapy by estimating the median change from that at baseline with corresponding 95% CIs. The Wilcoxon signed-rank test was conducted to test the null hypothesis: "The median change from baseline to 3 months after sclerotherapy in the population was greater than 0." The significance level was set at p < 0.025 (one-sided). This analysis was performed separately according to VM type and patient age (<6 years and \geq 6 years old). The occurrence of adverse events was assessed for safety evaluation.

- 296 All descriptive statistical analyses were performed using the SAS statistical
- 297 software (version 9.4; SAS Institute, NC).

298

299 **Results**

300 Participant selection, baseline demographics, and clinical

301 characteristics

302 Fig 1 illustrates the participant selection flowchart. Of the 45 patients who 303 provided informed consent, one was excluded owing to potential intracranial VM traffic 304 during screening. The remaining 44 patients fulfilled the inclusion criteria. All patients 305 were evaluated for the primary endpoint, and none of them discontinued treatment. Table 306 1 summarizes the baseline demographic and clinical characteristics of the patients. It is 307 noteworthy that for both cohorts, the full analysis set, per-protocol set, and safety analysis 308 set encompassed the same population under analysis for this study. This ensured 309 consistency and comparability across the various analyses conducted throughout the 310 research.

311

312 Table 1. Baseline Demographics and Clinical Characteristics of the Included

313 Patients.

| | | Cystic Type | Diffuse Type | All |
|------------|------|-------------|--------------|--------|
| | | n = 22 | n = 22 | n = 44 |
| Age (year) | Mean | 22.5 | 23.3 | 22.9 |
| | SD | 18.8 | 16.9 | 17.6 |
| | Min | 3 | 5 | 3 |

| | Median | 16.5 | 16.5 | 16.5 |
|---|------------|-----------|-----------|-----------|
| | Max | 78 | 59 | 78 |
| Sex (%) | Male | 13 (59.1) | 9 (40.9) | 22 (50.0) |
| | Female | 9 (40.9) | 13 (59.1) | 22 (50.0) |
| Body weight (kg) | Mean | 45.73 | 49.02 | 47.37 |
| | SD | 24.32 | 15.60 | 20.26 |
| | Min | 14.7 | 20.3 | 14.7 |
| | Median | 49.1 | 50.5 | 49.1 |
| | Max | 92.0 | 75.2 | 92.0 |
| Location of venous malformations (%) | Trunk | 5 (22.7) | 4 (18.2) | 9 (20.5) |
| | Upper limb | 3 (13.6) | 8 (36.4) | 11 (25.0) |
| | Lower | 5 (22.7) | 10 (45.5) | 15 (34.1) |
| | limb | | | |
| | Face | 5 (22.7) | 0 (0.0) | 5 (11.4) |
| | Oral | 1 (4.5) | 0 (0.0) | 1 (2.3) |
| | Neck | 3 (13.6) | 0 (0.0) | 3 (6.8) |
| Previous treatment | | | | |
| for venous | Yes | 10 (45.5) | 12 (54.5) | 22 (50.0) |
| malformations (%) | | | | |
| | No | 12 (54.5) | 10 (45.5) | 22 (50.0) |
| Treatment history | Initial | | | |
| of sclerotherapy | treatment | 17 (77.3) | 13 (59.1) | 30 (68.2) |
| for target lesion | | | | |

(%)

| Retreatme | 5 (22.7) | 9 (40.9) | 14 (31.8) |
|-----------|----------|----------|-----------|
| nt | | | |

314 Max, maximum; min, minimum; n, number; SD, standard deviation.

315

316 **Primary endpoint**

317 All 44 patients underwent sclerotherapy, and none of the patients with diffuse 318 VMs required additional treatment. Overall, a total of 26 patients (59.1%) achieved a VM 319 volume reduction $\geq 20\%$, including 16 patients with cystic lesions (72.7%, 95% CI: 320 51.85–86.85%) and 10 patients with diffuse lesions (45.5%, 26.92–65.34%). For both 321 cohorts, the percentage of patients achieving a reduction rate $\geq 20\%$ was statistically 322 significant compared with the pre-specified criterion of 20% (cystic lesions: p < 0.001, 323 diffuse lesions: p = 0.001). Data of patients who achieved a reduction rate $\ge 20\%$ are shown in Table 2, and the percentage change in lesion volume for each patient is shown in 324 325 Fig 4. The interobserver correlation coefficient (2,1) for the MRI analysis was 0.999 (n = 326 88, 99.8–100%). 327 328 Fig 4. Waterfall plot of the evaluated lesion volume. (A) Diagrams of cystic lesions 329 and diffuse lesions. (B) Diagrams for all cases. 330 331 Table 2. Patients Who Achieved \geq 20% Venous Malformation Volume Reduction 3

332 Months After the Intervention.

| Venous | No. of | Achieving a Reduction of at Least 20% | Р |
|--------|--------|---------------------------------------|---|
|--------|--------|---------------------------------------|---|

| Malformati | Patients | No. of | Percenta | 95% Confidence | Value |
|-----------------|----------|-----------|----------|----------------|-------|
| ons | | Achievers | ge | Intervals | |
| Cystic type | 22 | 16 | 72.7 | 51.85-86.85 | <0.00 |
| Diffuse type | 22 | 10 | 45.5 | 26.92–65.34 | 0.001 |
| All | 44 | 26 | 59.1 | 44.41-72.31 | |

333 The null hypothesis of this test: "The proportion of patients achieving $\geq 20\%$ venous

malformation volume reduction 3 months after sclerotherapy is < 20%."

The significance level of the test was 0.025 (on one side).

336 Test method: Test based on a binomial distribution.

337 Calculation method for confidence intervals: based on the score test.

338

339 Secondary endpoint

| 340 | The key | secondary | endpoint | was the | change i | n self-re | ported. | lesion- | associated |
|-----|---------|--------------|----------|---------|----------|-----------|-----------|---------|------------|
| 0.0 | | See Oneren j | • | | | | 0.010000, | 1001011 | |

341 pain scores from baseline to 3 months after sclerotherapy using the VAS or face scale.

342 Significant improvements in VAS scores were observed for both cohorts (cystic lesions

343 *vs.* diffuse lesions; 24-h maximum pain: n = 18, median: -2.0, p = 0.014 *vs.* n = 21,

344 median: -7.0, p = 0.013; 1-week maximum pain: n = 13, median: -2.0, p = 0.010 vs. n

345 = 20, median: -28.5, p < 0.001). Due to the limited sample size of patients aged ≤ 5

346 years, some statistical estimations and tests using the face scale-derived data could not

347 be conducted. Changes in pain scores are presented in Table 3.

349 Table. 3 Changes in Self-Reported, Lesion-Associated Pain Scores 3 Months After

350 Sclerotherapy.

| Venous | Scale | Age | Type of Pain | No. of | Median | 95% | Р |
|--------------|-------|-----------|--------------|----------|----------|-----------------|---------|
| Malformatio |) | | | Patients | Change | Confidence | Value |
| ns | | | | | From | Intervals | |
| | | | | | Baseline | | |
| Cystic type | VAS | ≥ 6 years | Maximum | 18 | -2.0 | -25.00 to 0.00 | 0.014 |
| | | | pain in 24 h | | | | |
| | | | Maximum | 13 | -2.0 | -51.00 to 0.00 | 0.010 |
| | | | pain for 1 | | | | |
| | | | week | | | | |
| | Face | 2–5 | Maximum | 2 | 0.0 | 0.00 to 0.00 | |
| | scale | years | pain in 24 h | | | | |
| | | | Maximum | 2 | -0.5 | -1.00 to 0.00 | 0.500 |
| | | | pain for 1 | | | | |
| | | | week | | | | |
| Diffuse type | VAS | ≥ 6 years | Maximum | 21 | -7.0 | -31.00 to -1.00 | 0.013 |
| | | | pain in 24 h | | | | |
| | | | Maximum | 20 | -28.5 | -34.00 to | < 0.001 |
| | | | pain for 1 | | | -16.00 | |
| | | | week | | | | |
| | Face | 2–5 | Maximum | 1 | 0.0 | | |
| | scale | years | pain in 24 h | | | | |

Maximum 1 0.0 — —

pain for 1

week

- 351 The null hypothesis of the test: "The median change in self-reported, lesion-associated
- pain scores from baseline to 3 months after sclerotherapy is ≥ 0 ."
- 353 The significance level of the test was 0.025 (on one side).
- 354 Method of testing: Wilcoxon signed-rank test.
- 355 Confidence intervals were calculated according to the method described by Hahn and
- 356 Meeker [28].

357

358 Safety evaluations

No cases of death or serious adverse events were reported. Adverse events of particular interest, defined as skin necrosis and visual impairment (for facial lesions) following administration, were not observed during the study period. Adverse events were documented in 42 patients (95.5%). Among them, one patient experienced a grade 3

363 adverse event related to pain, while nine patients experienced grade 2 adverse events.

364 These grade 2 events included three cases of pain; two of hemoglobinuria; and one each

365 of swelling, increased fibrin D-dimer, increased serum creatinine phosphokinase, and

366 ulnar nerve paralysis. Additionally, 32 patients reported grade 1 adverse events. Notably,

- 367 hemoglobinuria occurred in 23 patients (52%), including nine with cystic lesions
- 368 (40.9%) and 14 with diffuse lesions (63.6%). All cases of hemoglobinuria occurred on
- the day of drug administration, and haptoglobin therapy was initiated on the same or

370 subsequent day; all patients recovered within 1 month.

371

372 **Discussion**

373 Strengths of this study

- 374 This clinical trial is the first well-designed study to provide robust evidence 375 regarding the efficacy and safety of ethanolamine oleate for patients with 376 difficult-to-resect VMs. The rarity of VMs makes it challenging to conduct large-scale 377 trials, and the lack of clinically robust evidence hinders the pharmaceutical approval of 378 ethanolamine oleate in some countries, including Japan [11]. This high-quality study, 379 demonstrating positive outcomes, has the potential to pave the way for regulatory 380 approval in such regions. Patients affected by VMs face great challenges due to the rarity 381 of their disease and inadequate national-level support; therefore, this study holds promise 382 for the global recognition of ethanolamine oleate treatment.
- 383

Interpretation of the study endpoints

385 Regarding the primary endpoint, the majority of patients achieved $\geq 20\%$ VM 386 volume reduction 3 months after sclerotherapy. Specifically, 16 patients (72.7%) with 387 cystic lesions and 10 patients (45.5%) with diffuse lesions demonstrated a volume 388 reduction $\geq 20\%$. These findings suggest the utility of ethanolamine oleate administration 389 in reducing VM volume for both cystic and diffuse lesions, consistent with previous 390 reports [7,25]. Given that thrombus formation and lesion enlargement can induce diverse 391 symptoms in patients with VMs, a volume reduction $\geq 20\%$ is clinically significant. As 392 such, patients who achieved this reduction have reported improvements in symptoms 393 such as pain.

| 394 | Regarding the secondary endpoint, significant improvements in self-reported, |
|-----|---|
| 395 | lesion-associated pain scores were observed 3 months after sclerotherapy, which aligned |
| 396 | with the findings of previous studies [14,21,29-32]. Although the mechanism through |
| 397 | which pain is alleviated by sclerotherapy for VM is not currently well understood, the |
| 398 | following mechanisms are hypothesized. Upon injection into the blood vessel, the |
| 399 | sclerosing agent damages the endothelium, causing the vessel to contract, which |
| 400 | obstructed the blood flow. This may reduce abnormal blood flow and pressure, |
| 401 | potentially alleviating pain. Additionally, the sclerosing agent can strengthen the vessel |
| 402 | walls, reducing their leakage and dilation, which can also alleviate pain. Furthermore, the |
| 403 | reduced frequency of thrombus formation decreases the likelihood of thrombophlebitis, |
| 404 | contributing to pain reduction. |

405

406 Safety of this method

407 Regarding safety, hemoglobinuria was reported in approximately 52% of the 408 patients in our study, which was comparable to the prevalence reported in previous 409 Japanese clinical observational studies (27.7–50.0%) [7,14,33]. In cases where 410 hemoglobinuria occurs during sclerotherapy with ethanolamine oleate, there is a potential 411 risk of progression to acute renal failure [34]. Therefore, clinicians should be aware of the 412 importance of early administration of haptoglobin, a plasma fraction preparation [35]. In 413 a study by Fujiki et al. [33], early haptoglobin administration for hemoglobinuria 414 prevented renal damage in all cases, and these authors identified that a 5% ethanolamine 415 oleate dose ≥ 0.18 mL/kg was a predictive factor for gross hematuria. To avoid acute renal 416 failure, it is essential to disseminate information regarding the risk of hemoglobinuria 417 with ethanolamine oleate use through guidelines or similar resources. Interestingly, no

| 418 | cases of skin ulceration or skin necrosis were observed in the present study, whereas |
|-----|---|
| 419 | previous studies have reported incidence rates of 3.0-14.7% [7,21,36]. The absence of |
| 420 | these complications implies a safer treatment profile with our regimen. |
| 421 | |

422 Limitations of this study

423 Some limitations were noted in the present study. First, the study employed a 424 single-arm design and included a relatively limited sample size. Although this reflected 425 the rarity of the studied disease, this also limits the generalizability of our findings. 426 Nevertheless, our study population was comparable to that included in the trial that served as the basis for approval (44 patients), and our study employed a post-intervention 427 428 evaluation period of 3 months. Larger scale studies with longer follow-up periods are 429 needed to clarify our findings. Second, while no age restrictions were imposed in this 430 study, we were unable to recruit children ≤ 2 years of age, which is a significant 431 population affected by VMs. Lastly, the inclusion of some patients who lacked baseline 432 pain assessment data and the presence of age-related variations in pain scale 433 comprehension limited the applicability of a single pain assessment tool. 434

435 Conclusion

To the best of our knowledge, this is the first prospective clinical trial to expound the indications for ethanolamine oleate administration in patients with difficult-to-resect VMs in Japan. In our study population of 44 patients, ethanolamine oleate significantly reduced VM lesion volume and improved pain. Regarding safety, clinicians should be aware of the significance of early haptoglobin administration for drug-induced hemoglobinuria. Our results highlight the potential of ethanolamine oleate as a treatment

- 442 option for patients with difficult-to-resect VMs. Further studies with larger sample sizes
- 443 and longer follow-up durations are warranted to evaluate the long-term clinical outcomes
- 444 of this approach.
- 445

446 Acknowledgments

- 447 This study was supported by the Kobe Clinical and Translational Research Centre. We
- 448 thank all the staff for their involvement in this clinical trial.

449

450 Data sharing statement

- 451 Individual participant data underlying the results (text, tables, and figures) reported in this
- 452 article after de-identification will be shared following article publication. Requests will
- 453 be honored by researchers who provide a methodologically sound proposal and execute a
- 454 data-use agreement with Kyorin University. Requests should be directed to the
- 455 corresponding author by email.

456

457 **Declaration of interest**

Fuji Chemical Industries Co., Ltd. provided ethanolamine oleate for treatment during the
study period; however, the company had no role in this clinical trial. The authors declare
no conflict of interest.

461

462 **Role of sponsor**

- 463 The funders had no role in study design, data collection and analysis, decision to publish,
- 464 or preparation of the manuscript.
- 465

466 Ethics

- 467 This study was conducted using good clinical practice and adhered to the principles of the
- 468 Declaration of Helsinki. It was approved by the ethics committee of each hospital and
- 469 registered with the Japan Registry of Clinical Trials (Identifier: jRCT2051200046) under
- 470 the recommendations of the International Committee of Medical Journal Editors
- 471 (Registered on August 25, 2020). (<u>https://jrct.niph.go.jp/latest-detail/jRCT2051200046</u>).
- 472 Written informed consent was obtained from all patients or their parents/guardians. This
- 473 registry is independent of for-profit interests.
- 474

475 **Contributors' statement**

- 476 Tadashi Nomura conceptualized, designed, managed, and conducted the clinical trial and
- 477 collected the data.
- 478 Yasumasa Kakei conceptualized, designed, and managed the clinical trial and drafted the
- 479 manuscript.
- 480 Keiko Miyakoda conceptualized and designed the clinical trial and was responsible for
- 481 statistical analyses as a biostatistician.
- 482 Masakazu Kurita, Ayato Hayashi, Noriko Aramaki, Makoto Hikosaka, Shunsuke
- 483 Yuzuriha, Keigo Osuga, Yuki Iwashina, Taiki Nozaki, and Michio Ozeki conducted the
- 484 clinical trial and collected the data.

- 485 Mine Ozaki conceptualized, designed, managed, and conducted the clinical trial and
- 486 collected the data.
- 487 All authors approved the final manuscript and agreed to be accountable for all aspects of
- this study.

References

| 491 | 1. | Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants |
|-----|----|---|
| 492 | | and children: a classification based on endothelial characteristics. Plast Reconstr |
| 493 | | Surg. 1982;69: 412-422. doi: 10.1097/00006534-198203000-00002. |
| 494 | 2. | Hein KD, Mulliken JB, Kozakewich HP, Upton J, Burrows PE. Venous |
| 495 | | malformations of skeletal muscle. Plast Reconstr Surg. 2002;110: 1625-1635. |
| 496 | | doi: 10.1097/01.PRS.0000033021.60657.74. |
| 497 | 3. | Carabin J, Bouhamama A, Vaz G, Cuinet M, Ricoeur A, Thibaut A, et al. |
| 498 | | Percutaneous cryoablation of symptomatic intramuscular venous malformation. J |
| 499 | | Vasc Interv Radiol. 2020;31: 558-563.e3. doi: 10.1016/j.jvir.2019.10.024. |
| 500 | 4. | Kang GB, Bae YC, Nam SB, Bae SH, Sung JY. The usefulness of surgical |
| 501 | | treatment in slow-flow vascular malformation patients [published correction |
| 502 | | appears in Arch Plast Surg. 2017;44: 575-576]. Arch Plast Surg. 2017;44: |
| 503 | | 301-307. doi: 10.5999/aps.2017.44.4.301. |
| 504 | 5. | Roh YN, Do YS, Park KB, Park HS, Kim YW, Lee BB, et al. The results of |
| 505 | | surgical treatment for patients with venous malformations. Ann Vasc Surg. |
| 506 | | 2012;26: 665-673. doi: 10.1016/j.avsg.2011.12.004. |
| 507 | 6. | Lee BB, Do YS, Byun HS, Choo IW, Kim DI, Huh SH. Advanced management of |

| 508 | | venous malformation with ethanol sclerotherapy: mid-term results. J Vasc Surg. |
|-----|----|--|
| 509 | | 2003;37: 533-538. doi: 10.1067/mva.2003.91. |
| 510 | 7. | Kaji N, Kurita M, Ozaki M, Takushima A, Harii K, Narushima M, et al. |
| 511 | | Experience of sclerotherapy and embolosclerotherapy using ethanolamine oleate |
| 512 | | for vascular malformations of the head and neck. Scand J Plast Reconstr Surg |
| 513 | | Hand Surg. 2009;43: 126-136. doi: 10.1080/02844310902840296. |
| 514 | 8. | Górriz E, Carreira JM, Reyes R, Gervás C, Pulido JM, Pardo MD, et al. |
| 515 | | Intramuscular low flow vascular malformations: treatment by means of direct |
| 516 | | percutaneous embolization. Eur J Radiol. 1998;27: 161-165. doi: |
| 517 | | 10.1016/s0720-048x(97)00045-4. |
| 518 | 9. | Mimura H, Akita S, Fujino A, Jinnin M, Ozaki M, Osuga K, et al. Japanese |
| 519 | | clinical practice guidelines for vascular anomalies 2017. J Dermatol. 2020;47: |
| 520 | | e138-e183. doi: 10.1111/1346-8138.15189. |
| 521 | 10 | Mulliken JB, Burrows PE, Fishman SJ. Mulliken and Young's vascular |
| 522 | | anomalies: hemangiomas and malformations. 2nd ed. New York: Oxford |
| 523 | | University Press; 2013. pp. 662-672. doi: |
| 524 | | 10.1093/med/9780195145052.001.0001. |
| 525 | 11 | . Heit JJ, Do HM, Prestigiacomo CJ, Delgado-Almandoz JA, English J, Gandhi |

| 526 | CD, et al. Guidelines and parameters for percutaneous sclerotherapy for the |
|-----|--|
| 527 | treatment of head and neck venous and lymphatic malformations. |
| 528 | NeuroIntervent Surg. 2017;9: 611-617. doi: 10.1136/neurintsurg-2015-012255. |
| 529 | 12. Rabe E, Breu FX, Cavezzi A, Smith PC, Frullini A, Gillet JL, et al. European |
| 530 | guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29: |
| 531 | 338-354. doi: 10.1177/0268355513483280. |
| 532 | 13. Uehara S, Osuga K, Yoneda A, Oue T, Yamanaka H, Fukuzawa M. Intralesional |
| 533 | sclerotherapy for subcutaneous venous malformations in children. Pediatr Surg |
| 534 | Int. 2009;25: 709-713. doi: 10.1007/s00383-009-2414-y. |
| 535 | 14. Ozaki M, Kurita M, Kaji N, Fujino T, Narushima M, Takushima A, et al. Efficacy |
| 536 | and evaluation of safety of sclerosants for intramuscular venous malformations: |
| 537 | clinical and experimental studies. Scand J Plast Reconstr Surg Hand Surg. |
| 538 | 2010;44: 75-87. doi: 10.3109/02844310903569725. |
| 539 | 15. Mimura H, Kanazawa S, Yasui K, Fujiwara H, Hyodo T, Mukai T, et al. |
| 540 | Percutaneous sclerotherapy for venous malformations using polidocanol under |
| 541 | fluoroscopy. Acta Med Okayama. 2003;57: 227-234. doi: 10.18926/AMO/51909. |
| 542 | 16. Nakahata K, Uehara S, Zenitani M, Nakamura M, Osuga K, Okuyama H. Patient |
| 543 | satisfaction after sclerotherapy of venous malformations in children. Pediatr Int. |

- 544 2016;58: 721-725. doi: 10.1111/ped.12880.
- 545 17. Yamaki T, Nozaki M, Sasaki K. Color duplex-guided sclerotherapy for the 546 treatment of venous malformations. Dermatol Surg. 2000;26: 323-328. doi: 547 10.1046/j.1524-4725.2000.99248.x. 548 18. Jo JY, Chin JH, Park PH, Ku SW. Cardiovascular collapse due to right heart 549 failure following ethanol sclerotherapy: A case report. Korean J Anesthesiol. 550 2014;66: 388-391. doi: 10.4097/kjae.2014.66.5.388. 551 19. Marrocco-Trischitta MM, Guerrini P, Abeni D, Stillo F. Reversible cardiac arrest 552 after polidocanol sclerotherapy of peripheral venous malformation. Dermatol 553 Surg. 2002;28: 153-155. doi: 10.1046/j.1524-4725.2002.00344.x. 554 20. Horbach SER, Lokhorst MM, Saeed P, de Goüyon Matignon de Pontouraude 555 CMF, Rothová A, van der Horst CMAM. Sclerotherapy for low-flow vascular 556 malformations of the head and neck: A systematic review of sclerosing agents. J 557 Plast Reconstr Aesthet Surg. 2016;69: 295-304. doi: 10.1016/j.bjps.2015.10.045. 558 21. Hoque S, Das BK. Treatment of venous malformations with ethanolamine 559 oleate: a descriptive study of 83 cases. Pediatr Surg Int. 2011;27: 527-531. doi: 560 10.1007/s00383-010-2824-x. 561 22. Kobayakawa M, Kokubu S, Hirota S, Koizumi J, Nishida N, Yasumoto T, et al.

| 562 | Short-term safety and efficacy of balloon-occluded retrograde transvenous |
|-----|---|
| 563 | obliteration using ethanolamine oleate: Results of a prospective, multicenter, |
| 564 | single-arm trial. J Vasc Interv Radiol. 2017;28: 1108-1115.e2. doi: |
| 565 | 10.1016/j.jvir.2017.03.041. |
| 566 | 23. Masaki M, Obara K, Suzuki S, Orikasa K, Mitsuhashi H, Iwasaki K, et al. The |
| 567 | destructive effects of sclerosant ethanolamine oleate on mammalian vessel |
| 568 | endothelium. Gastroenterol Jpn. 1990;25: 230-235. doi: 10.1007/BF02776821. |
| 569 | 24. Bagga B, Goyal A, Das A, Bhalla AS, Kandasamy D, Singhal M, et al. |
| 570 | Clinicoradiologic predictors of sclerotherapy response in low-flow vascular |
| 571 | malformations. J Vasc Surg Venous Lymphat Disord. 2021;9: 209-219.e2. doi: |
| 572 | 10.1016/j.jvsv.2020.03.011. |
| 573 | 25. Alexander MD, McTaggart RA, Choudhri OA, Marcellus ML, Do HM. |
| 574 | Percutaneous sclerotherapy with ethanolamine oleate for venous malformations |
| 575 | of the head and neck. J Neurointerv Surg. 2014;6: 695-698. doi: |
| 576 | 10.1136/neurintsurg-2013-010924. |
| 577 | 26. Rautio R, Saarinen J, Laranne J, Saleniui JP, Keski-Nisula L. Endovascular |
| 578 | treatment of venous malformations in extremities: Results of sclerotherapy and |
| 579 | the quality of life after treatment. Acta Radiol. 2004;45: 397-403. doi: |

580 10.1080/02841850410004913.

581 27. Wong DL, Baker CM. Pain in children: Comparison of assessment scales. 582 Pediatr Nurs. 1988;14: 9-17. 583 28. Hahn GJ, Meeker WO. Statistical intervals: A guide for practitioners. New York: 584 John Wiley & Sons; 1991. 585 29. Das BK, Hoque S. Treatment of venous malformations with ethanolamine oleate. 586 Asian J Surg. 2008;31: 220-224. doi: 10.1016/S1015-9584(08)60091-3. 587 30. Ribeiro MC, de Mattos Camargo Grossmann S, do Amaral MBF, de Castro WH, 588 Navarro TP, Procopio RJ, et al. Effectiveness and safety of foam sclerotherapy 589 with 5% ethanolamine oleate in the treatment of low-flow venous malformations 590 in the head and neck region: A case series. Int J Oral Maxillofac Surg. 2018;47: 591 900-907. doi: 10.1016/j.ijom.2017.12.004. 592 31. Mimura H, Fujiwara H, Hiraki T, Gobara H, Mukai T, Hyodo T, et al. Polidocanol 593 sclerotherapy for painful venous malformations: evaluation of safety and efficacy 594 in pain relief. Eur Radiol. 2009;19: 2474-2480. doi: 10.1007/s00330-009-1442-2. 595 32. Nagata S, Tanaka N, Kuhara A, Kugiyama T, Tanoue S, Koganemaru M, et al. 596 Value of fat-suppressed T2-weighted imaging for predicting short-term pain relief 597 after sclerotherapy for venous malformations in the extremities. Jpn J Radiol.

598 2023;41: 1157-1163. doi: 10.1007/s11604-023-01442-x. Epub 2023 May 12.

599 33. Fujiki M, Ozaki M, Kurachi I, Iwashina Y, Takushima A. Risk factors for 600 macroscopic haemoglobinuria after sclerotherapy using ethanolamine oleate for 601 venous malformations. Eur J Vasc Endovasc Surg. 2019;58: 105-111. doi: 602 10.1016/j.ejvs.2018.12.018. 603 34. Yamaki T, Nozaki M, Sakurai H, Takeuchi M, Soejima K, Kono T. Prospective 604 randomized efficacy of ultrasound-guided foam sclerotherapy compared with 605 ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous 606 malformations. J Vasc Surg. 2008;47: 578-584. doi: 10.1016/j.jvs.2007.11.026. 607 35. Hashizume M, Kitano S, Yamaga H, Sugimachi K. Haptoglobin to protect against 608 renal damage from ethanolamine oleate sclerosant. Lancet. 1988;2: 340-341. doi: 609 10.1016/s0140-6736(88)92400-2. 610 36. Costa JR, Torriani MA, Hosni ES, D'Avila OP, de Figueiredo PJ. Sclerotherapy 611 for vascular malformations in the oral and maxillofacial region: treatment and 612 follow-up of 66 lesions. J Oral Maxillofac Surg. 2011;69: e88-e92. doi: 613 10.1016/j.joms.2010.06.204. 614





















% Change from baseline